Erivedge (vismodegib)
- Region
- 🇪🇺 EU
- Active substance
- vismodegib
- Company
- Roche Registration GmbH
- Status
- Authorised
- Therapeutic area
- Carcinoma, Basal Cell
- CHMP opinion
- Thu 25 Apr 2013
- EU approval
- Fri 12 Jul 2013
- Application
- EMEA/H/C/002602
- ATC
- L01XX43
- Official record
- www.ema.europa.eu
Indication
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Regulatory milestones
No milestones recorded in the last year.
Follow Erivedge
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.